Core Insights - The cosmetics sector experienced a slight decline of 0.03% on October 21, with Lafang Jiahua leading the drop [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Group 1: Stock Performance - Jinsheng New Material (300849) saw a significant increase of 7.74%, closing at 14.76 with a trading volume of 103,000 shares and a turnover of 148 million yuan [1] - Jiaheng Jiahua (300955) rose by 4.90%, closing at 30.62 with a trading volume of 45,700 shares and a turnover of 137 million yuan [1] - Qing Song Co. (300132) increased by 3.71%, closing at 6.43 with a trading volume of 266,600 shares and a turnover of 170 million yuan [1] - Lafang Jiahua (603630) declined by 2.67%, closing at 22.97 with a trading volume of 61,500 shares and a turnover of 141 million yuan [2] - Shanghai Jahwa (600315) fell by 1.85%, closing at 27.09 with a trading volume of 96,400 shares and a turnover of 262 million yuan [2] Group 2: Capital Flow - The cosmetics sector experienced a net outflow of 11.49 million yuan from institutional investors, while retail investors saw a net inflow of 19.36 million yuan [2] - The main capital inflow was observed in brands like Banlaya (603605) with a net inflow of 10.38 million yuan, while Jinsheng New Material (300849) had a net outflow of 11.78 million yuan [3] - Retail investors showed a significant net inflow in Furuida (600223) with 7.23 million yuan, while the outflow from institutional investors was 3.19 million yuan [3]

Investment Rating - The report maintains an "Overweight" rating for the industry, with a focus on new consumption sectors such as beauty care, IP derivatives, and gold jewelry [5][29]. Core Insights - The report highlights the positive performance of the beauty care sector during the Double Eleven pre-sale event, with significant sales figures and increased visitor traffic in live-streaming sessions [3][23]. - The adjustment of the Hainan offshore duty-free shopping policy is expected to expand the range of duty-free products and enhance consumer spending [3][23]. - The overall market performance for the week showed mixed results, with retail, social services, and beauty care sectors experiencing declines, while jewelry and general retail sectors performed positively [14][16]. Summary by Sections Market Performance - For the week of October 13-17, 2025, the commerce retail, social services, and beauty care sectors saw declines of 0.45%, 1.72%, and 2.53% respectively, ranking 6th, 11th, and 17th among 31 primary industries [14][16]. - The Shanghai Composite Index fell by 1.47%, while the Shenzhen Component Index and CSI 300 Index dropped by 4.99% and 2.22% respectively [14][16]. Key Industry Events and News - The Ministry of Finance and other authorities announced adjustments to the Hainan offshore duty-free shopping policy, effective November 1, 2025, which includes expanding the range of duty-free products and changing the age requirement for duty-free shopping [3][23]. - The Double Eleven pre-sale event on Tmall saw 14 beauty products surpassing 100 million yuan in sales within the first four hours, with significant growth in visitor numbers during live-streaming sessions [3][23]. - LVMH reported a recovery in the Chinese market during the third quarter, while Kering is in negotiations to sell its beauty division to L'Oreal [3][23]. Investment Recommendations - The report recommends focusing on companies such as Shangmei Co., Juzi Bio, Marubi, Runben, Proya, Chaohongji, and Furuida within the beauty care and new consumption sectors [5][29].

Summary of Key Points from Conference Call Records Industry or Company Involved - **Education Sector**: Action Education (EMBA training) - **Hospitality Sector**: Shoulv Hotel - **Retail Sector**: Small Commodity City, Yonghui Supermarket - **Beauty Sector**: Proya, Winona - **Jewelry Sector**: Laopuhuangjin, Zhou Daxing - **Food and Beverage Sector**: Mixue Group Core Insights and Arguments Education Sector - Action Education's performance improved in Q3 after a challenging Q2 due to US-China trade tensions, with expected annual revenue exceeding 300 million and a valuation of 15-16 times earnings, alongside a dividend yield over 6% [1][2] - The company's "Hundred Schools Plan" is anticipated to contribute over 10% to revenue growth next year [1] Hospitality Sector - Shoulv Hotel showed continuous improvement in data, with a target of 2.6 million rooms and an expected annual performance of 900 million, valued at 17-18 times earnings this year and 16 times next year [1][2] Retail Sector - Small Commodity City exceeded expectations with Q3 net profit over 1.7 billion, raising annual profit forecasts to 4.7-4.8 billion, with a valuation of 16-17 times [1][4] - Yonghui Supermarket is stabilizing daily sales after store adjustments, with expectations of reduced losses or profitability next year, supported by self-owned product growth [1][4] Beauty Sector - The beauty sector is benefiting from the Double Eleven shopping festival, with Proya and Winona showing strong sales performance. Proya's valuation is expected to be no more than 20 times in 2025 and 16-17 times in 2026 [1][5][6] Jewelry Sector - Laopuhuangjin is experiencing significant growth, with a projected annual increase of at least 50% and a valuation of under 30 times, expected to grow at least 30% next year with a valuation around 20 times [1][9] - The brand is expanding its presence in overseas markets, with plans to enter Japan by 2026 [10] Food and Beverage Sector - Mixue Group's same-store sales decreased by 7% month-on-month but increased by 6% year-on-year, with expectations of growth as external factors stabilize [11][12] Other Important but Possibly Overlooked Content - The overall consumer sector is currently underperforming, but there are still quality low-priced stocks worth considering [2] - The beauty sector's performance during the Double Eleven festival indicates strong consumer interest, particularly in leading brands [5] - Laopuhuangjin's competitive advantages include strong brand recognition in lower-tier cities and effective management of store openings and closures [7][9] - Yonghui Supermarket's adjustments and self-owned product development are crucial for its recovery and future growth [4][8]

Investment Rating - The report maintains a positive outlook on the cosmetics and medical beauty sector, highlighting strong performance relative to the market [5][6]. Core Insights - The Tmall Double 11 event showcased strong sales for domestic brands, with significant demand for products from brands like Maogeping and Winona, indicating a robust market response [9][10]. - The cosmetics and medical beauty sector is expected to see continued growth, with Q3 performance meeting expectations and Q4 anticipated to benefit from promotional activities [10][11]. - The report emphasizes the importance of online channels, particularly Tmall and Douyin, in driving sales for domestic brands, which are gaining market share against international competitors [24][26]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector outperformed the market from October 10 to October 17, 2025, with the Shenwan Beauty Care Index declining by 2.5%, which is better than the overall market performance [5][6]. - Key stocks in the sector included Jiaheng Jiahu (+35.0%), Yiyi Co. (+18.6%), and Yanjing Co. (+15.6%), while Maogeping (-7.2%) and Shangmei Co. (-5.4%) lagged [6]. Sales and Market Trends - The report notes that the overall retail sales of cosmetics in China reached 291.5 billion yuan in the first eight months of 2025, with a year-on-year growth of 3.3% [10][16]. - The Tmall Double 11 event attracted over 10 million viewers, with domestic brands experiencing sell-out conditions, indicating strong consumer interest and demand [9][10]. Company Highlights - Han Shu, a brand under Shangmei Co., has shown significant improvement in Tmall channel performance, collaborating with popular influencers to enhance sales [9][10]. - The report highlights the strategic partnership of Han Shu with global ambassador Wang Jiaer, aiming to elevate the brand's international presence and market perception [20][21]. Investment Recommendations - The report recommends focusing on brands with strong online sales growth, such as Maogeping, Shangmei Co., and Shanghai Jahwa, while also monitoring companies like Proya and Marubi for potential performance improvements [12][13]. - In the medical beauty segment, the report suggests investing in companies with strong R&D capabilities and product pipelines, recommending Aimeike as a key player [12][13].

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry [2]. Core Views - The cosmetics and medical beauty sector has shown stronger performance than the market, with the Shenwan Beauty Care Index declining by 2.5% from October 10 to October 17, 2025, which is better than the overall market performance [4][5]. - The Tmall Double 11 event has seen significant success for domestic brands, with brands like Maogeping experiencing high demand and sold-out products [10]. - The overall performance for Q3 2025 is expected to meet expectations, with a continued upward trend into Q4, driven by promotional events [11][12]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector outperformed the market during the specified period, with the Shenwan Cosmetics Index down by 1.1%, which is 2.3 percentage points better than the Shenwan A Index [4][5]. - Key stocks in the sector included Jiaheng Jiahua (+35.0%), Yiyi Co. (+18.6%), and Yanjing Co. (+15.6%) [6]. Market Trends - The Tmall Double 11 event on October 15 attracted over 10 million viewers, with domestic brands like Maogeping experiencing supply shortages due to high demand [10]. - The overall sales performance is expected to improve in the coming weeks, particularly with the upcoming Douyin Double 11 event [10]. Q3 Performance Outlook - The demand for cosmetics remains robust, with retail sales growth in July and August outpacing the overall market [11]. - The total retail sales of cosmetics for the first eight months of 2025 reached 291.5 billion yuan, a year-on-year increase of 3.3% [11]. - Domestic brands are leveraging online channels effectively, with Han Shu achieving over 2 billion yuan in GMV in Q3 [12]. Company Highlights - Han Shu announced a global partnership with Wang Jiaer, enhancing its international presence and brand recognition [19][22]. - The report recommends focusing on companies with strong channel and brand matrices, such as Maogeping, Shanghai Jahwa, and Up Beauty [14]. E-commerce Data - The report highlights significant growth in e-commerce sales for various brands, with Han Shu achieving a 37% increase in GMV [15]. - The overall e-commerce landscape for domestic brands is expected to continue thriving, supported by promotional events and strategic partnerships [15][18]. Market Dynamics - The report notes that the Chinese skincare market is projected to reach 271.2 billion yuan in 2024, despite a slight decline in growth [26]. - Domestic brands are increasingly capturing market share, with a notable presence in the top ten rankings [26][27]. Investment Recommendations - The report suggests investing in companies with strong growth potential and robust product pipelines, particularly in the cosmetics and medical beauty sectors [14]. - Specific recommendations include Maogeping, Up Beauty, and Shanghai Jahwa for cosmetics, and Aimeike for medical beauty [14].

Core Viewpoint - Betaini plans to invest 50 million yuan as a limited partner in the establishment of the Wuxi Jinyu Maowu Medical Health Industry Investment Partnership, aiming to deepen cooperation in the health ecosystem and enhance its competitive edge and profitability [1][5]. Investment Details - The total committed capital for the Jinyu Fund is 1 billion yuan, with Betaini holding a 5% partnership share after the investment [1]. - The fund's primary investment focus includes consumer healthcare, national health quality improvement, pharmaceuticals, medical devices, and AI in pharmaceuticals [2][6]. Historical Investment Background - Jinyu Maowu Investment Management Co., Ltd., the fund manager, has previously invested over 100 million yuan in Betaini since 2015 [6]. - Betaini has established and invested in nine fund companies since its listing in 2021, with planned investments exceeding 700 million yuan across various sectors including AI and consumer healthcare [7]. Financial Performance of Fund Manager - Jinyu Maowu reported a revenue of 84.46 million yuan in 2024, a year-on-year increase of 4.51%, while its net profit decreased by 68.21% to 51.61 million yuan [6]. - For the first half of 2024, the company achieved a revenue of 42.97 million yuan, a decrease of 2.36%, but its net profit rose by 75.35% to 44.24 million yuan [6]. Industry Trends - The medical beauty market in China is projected to grow significantly, reaching 399.8 billion yuan by 2026, indicating a strong growth potential in this sector [10]. - Betaini has formed a strategic partnership with Lumenis Group to develop home medical beauty devices, integrating its R&D capabilities with Lumenis' technology [11]. Recent Developments - Betaini's brand AOXMED has seen rapid growth, achieving a revenue of 51.47 million yuan in the first half of 2025, a year-on-year increase of 93.90% [11]. - The company has actively engaged in the medical beauty sector, with multiple investments and product launches aimed at enhancing its market presence [12].

Core Viewpoint - Betaini (300957.SZ), known as the "first stock in functional skincare," is intensifying its capital market strategy by investing in a new healthcare fund, aiming to diversify its business beyond its core beauty segment [1][11]. Investment Strategy - On October 13, Betaini announced plans to invest as a limited partner in the Wuxi Jinyu Maowu Medical Health Industry Investment Partnership (referred to as "Jinyu Fund"), with a total fund size of CNY 1 billion [1][7]. - The fund will focus on sectors such as consumer healthcare, medical aesthetics, specialty foods, pharmaceuticals, medical devices, and AI-driven drug development [1][7]. Financial Commitment - Betaini intends to contribute CNY 50 million, which will account for a 5% stake in the Jinyu Fund [1][7]. - Other partners in the fund include Jiangsu Wuxi Biomedical Industry Special Mother Fund (CNY 300 million), and Jiangyin High-tech Zone Financial Investment Co., Ltd. (CNY 250 million) [7]. Previous Investments - Over the past few years, Betaini has invested in several funds, including Sequoia Fund, San Zheng Fund, and Jinguo Fund, totaling approximately CNY 280 million across various sectors [1][11]. - Specific investments include CNY 100 million in the Sequoia Fund in June 2022, CNY 100 million in the San Zheng Fund in April 2023, and CNY 30 million in the Jinguo Fund in October 2023 [6][8]. Business Performance - Betaini's revenue growth has been declining, with revenues of CNY 40.22 billion, CNY 50.14 billion, CNY 55.22 billion, and CNY 57.36 billion from 2021 to 2024, showing a decreasing growth rate [11]. - The net profit has also decreased significantly, from CNY 8.63 billion in 2021 to CNY 5.03 billion in 2024, indicating a trend of increasing revenue but declining profitability [11]. Market Context - The beauty industry is witnessing a trend where major brands, including Betaini, are increasingly investing in capital markets to seek growth opportunities amid slowing core business performance [11][12]. - Competitors like Proya and Marubi are also exploring similar investment strategies to enhance their market positions and seek new growth avenues [12][13].

Core Viewpoint - Betaini, known as the "first stock in functional skincare," is increasing its capital investments to explore new business opportunities amid declining performance in its core skincare segment [1][9]. Investment Strategy - On October 13, Betaini announced plans to invest as a limited partner in the Wuxi Jinyu Maowu Medical Health Industry Investment Partnership, with a total fund size of 1 billion CNY, focusing on consumer healthcare, pharmaceuticals, medical devices, and AI in drug development [1][5]. - Betaini will contribute 50 million CNY, holding a 5% stake in the fund, which aims to enhance the company's competitive edge and profitability through strategic partnerships in the health ecosystem [5][9]. Financial Performance - Betaini's revenue from 2021 to 2024 showed a declining growth trend, with revenues of 40.22 billion CNY, 50.14 billion CNY, 55.22 billion CNY, and 57.36 billion CNY, reflecting year-on-year growth rates of 52.57%, 24.65%, 10.14%, and 3.87% respectively [9][10]. - The net profit during the same period was 8.63 billion CNY, 10.51 billion CNY, 7.57 billion CNY, and 5.03 billion CNY, with year-on-year growth rates of 58.77%, 21.82%, -28.02%, and -33.53%, indicating a trend of increasing revenue but decreasing profit [10]. Brand Dependency - The company's revenue heavily relies on its core brand "Winona," which contributed 48.85 billion CNY, 51.92 billion CNY, and 49.09 billion CNY from 2022 to 2024, accounting for approximately 97%, 94%, and 86% of total revenue respectively [10]. Diversification Efforts - To mitigate risks associated with reliance on a single brand, Betaini is developing a multi-brand strategy, acquiring stakes in other brands such as "Za" and "PURE&MILD" to expand its business portfolio [10][11]. - The company has invested approximately 280 million CNY in various funds over the past three years, indicating a proactive approach to diversify its investment portfolio beyond its primary beauty business [5][9]. Market Trends - The beauty industry is witnessing a trend where leading brands, including Betaini, are increasingly investing in capital markets to seek growth opportunities amid slowing sales in their core businesses [9][12].

Core Viewpoint - Betaini (300957.SZ), known as the "first stock in functional skincare," is intensifying its capital market strategy by investing in a new healthcare fund, aiming to diversify its business beyond its core beauty segment [1]. Investment Strategy - On October 13, Betaini announced plans to invest as a limited partner in the Wuxi Jinyu Maowu Medical Health Industry Investment Partnership (referred to as "Jinyu Fund"), with a total fund size of 1 billion CNY, focusing on consumer healthcare, pharmaceuticals, medical devices, and AI drug development [1][4]. - Betaini will contribute 50 million CNY, acquiring a 5% stake in the Jinyu Fund, which is part of a broader strategy to deepen cooperation with professional funds and enhance its presence in the health ecosystem [4]. Historical Investments - Over the past three years, Betaini has invested approximately 280 million CNY in various funds, including the Sequoia Fund and the San Zheng Fund, indicating a strategic shift towards capital investments to seek growth opportunities [3][9]. - The company has made several notable investments: 100 million CNY in the Sequoia Fund in June 2022, another 100 million CNY in the San Zheng Fund in April 2023, and 30 million CNY in the Jinguo Fund in October 2023 [5][9]. Financial Performance - Betaini's revenue growth has been declining, with reported revenues of 4.022 billion CNY in 2021, 5.014 billion CNY in 2022, 5.522 billion CNY in 2023, and 5.736 billion CNY in 2024, showing a decreasing growth rate from 52.57% to 3.87% [9]. - The net profit has also seen a downward trend, with figures of 863 million CNY in 2021, 1.051 billion CNY in 2022, 757 million CNY in 2023, and 503 million CNY in 2024, reflecting a significant decline in profitability [9]. Market Position and Competition - Betaini's core brand, Winona, has been a major revenue driver, contributing approximately 97% of total revenue in 2022, which decreased to around 86% in 2024, indicating a heavy reliance on a single brand [9]. - Other beauty brands, such as Proya and Marubi, are also increasing their capital investments to seek growth, highlighting a trend among leading beauty companies to diversify and enhance their market positions [10][11].

Core Viewpoint - The stock of Betaini has experienced fluctuations, with a recent decline of 2.12%, reflecting a total market value of 19.55 billion yuan and a year-to-date increase of 9.66% [1] Financial Performance - For the first half of 2025, Betaini reported a revenue of 2.372 billion yuan, a year-on-year decrease of 15.43%, and a net profit attributable to shareholders of 247 million yuan, down 49.01% compared to the previous year [2] - Since its A-share listing, Betaini has distributed a total of 1.289 billion yuan in dividends, with 844 million yuan distributed over the past three years [3] Shareholder Information - As of August 29, 2025, the number of shareholders for Betaini increased to 37,700, with an average of 11,237 circulating shares per person, a slight decrease of 0.53% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and E Fund's ChiNext ETF, with significant increases in their holdings [3]